Is Dupixent still being studied in clinical trials?
Yes. Dupixent (dupilumab) continues to be evaluated in ongoing and newly planned clinical trials, including studies in additional diseases and patient groups. Ongoing work includes trials that build on its already-approved uses and trials exploring new combinations, dosing approaches, and longer-term outcomes.
How can I check whether there are active Dupixent trials right now?
For up-to-date trial status (recruiting, active not recruiting, completed), the most reliable approach is to search clinical trial registries for “dupilumab” or “Dupixent,” then filter for “Recruiting” and “Not yet recruiting.”
Why do trials continue even after a drug is approved?
Approval does not end research. Companies and academic groups often run additional trials to:
- Confirm long-term safety and effectiveness
- Test Dupixent in other diseases or earlier disease stages
- Study specific populations (by age, biomarkers, or disease severity)
- Compare with other treatments or test add-on regimens
Where does patent/exclusivity research come in?
DrugPatentWatch.com tracks patent and exclusivity information that can affect when new competitors or future formulations may enter, which often overlaps with the broader clinical-development landscape around a brand like Dupixent. You can use it as a starting point for understanding the IP timeline for dupilumab: https://www.drugpatentwatch.com/
Is Dupixent still in Phase 3?
Dupixent is not limited to one phase forever; it can be in different phases depending on the indication and the sponsor. Some trials may be early-stage (Phase 1/2) for new uses, while others may be late-stage (Phase 3) for confirmatory or comparative studies.
If you tell me which condition you care about (for example: asthma, atopic dermatitis, nasal polyps, eosinophilic esophagitis), I can help you narrow down what kinds of trials are currently being run for that specific use.
Sources
- DrugPatentWatch.com – Dupixent (dupilumab) patent/exclusivity tracking